Product Code: RP-ID-10324799 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10324799
Market Overview:
Impact analysis of COVID-19 on Hydroxychloroquine Sulphate Global Market Outlook 2026
Hydroxychloroquine Sulphate Market Analysis – 2020-2026
Hydroxychloroquine sulphate or hydroxychloroquine is an antimalarial drug which is certified and approved for medical use globally for the treatment and prevention of certain types of diseases such as malaria, systemic lupus erythematosus, and rheumatoid arthritis, among several others. The drug is sold under the name Plaquenil and is taken orally. The market for hydroxychloroquine sulfate is projected to grow at a CAGR of 5.7% during the forecast period, i.e, 2020-2026. The market is anticipated to attain a significantly high market value of USD 1,405.7 million by the end of 2026.
Hydroxychloroquine sulphate market is segmented by type, by application and by region, out of which the segment for type is further segmented into USP standard grade, EP standard grade, pharmaceutical standards grade and others. The segment for USP standards grade is predicted to hold the largest share in the market with a market value of around USD 496.4 million by the end of 2026. In addition to this, this segment is projected to grow with the highest growth rate over the forecast period. Based on the application segment, the market for hydroxychloroquine is segmented into rheumatoid joint, adolescent chronic joint, discoid & systemic lupus erythmatosus and skin lesions. Out of these, the segment for rheumatoid joint is anticipated to hold the leading share in the market on account of growing incidences of the disease all over the world.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to witness the highest share in the market with the largest market in the United States, which further is the projected to be the fastest growing market in the region. The market for hydroxychloroquine sulphate in Asia Pacific is estimated to hold the leading share in the market as a result of increasing research and development activities for the manufacture and marketing of this drug.
Some of the key industry leaders in the global hydroxychloroquine sulphate market are Sandoz International Gmbh, Teva Pharmaceutical Industries Ltd., Mylan N.V., Hikma Pharmaceuticals Plc, Ipca Laboratories Limited, Shanghai Pharmaceutical Group Co., Ltd., Jiangsu Shenhua Pharmaceutical Co., Ltd., Sanofi S.A., Taj Pharmaceuticals Limited and Cinkate Corporation.
Sandoz International Gmbh, Teva Pharmaceutical Industries Ltd., Mylan N.V., Hikma Pharmaceuticals Plc, Ipca Laboratories Limited, Shanghai Pharmaceutical Group Co., Ltd., Jiangsu Shenhua Pharmaceutical Co., Ltd., Sanofi S.A., Taj Pharmaceuticals Limited and Cinkate Corporation
Related Reports
Proof of Quality & Reliability
